Changchun Genescience Pharmaceuticals Co. Ltd. has reported GSC-000829, a novel and selective FGFR2/FGFR3 inhibitor being developed for the potential treatment of cancer.

We have previously demonstrated that several members of the Fibroblast Growth Factor Receptor (FGFR) family are transiently phosporylated upon TBI; the availability for drug repurposing of FGFR ...

Weill Cornell Medicine researchers have determined the full-length structure of a blood pressure-regulating hormone receptor for the first time, uncovering how it functions, which may enable better ...

Weill Cornell Medicine researchers have determined the full-length structure of a blood pressure-regulating hormone receptor for the first time, uncovering how it functions, which may enable ...